Lilly plans to open Lilly Gateway Labs site in Philadelphia

The new Gateway Labs site will occupy 44,000 square feet of 2300 Market, a life sciences facility in Center City newly developed and operated by Breakthrough Properties.

As per the release, Biotechs based in the site will have access to fully equipped wet lab facilities alongside the scientific engagement that has been the hallmark of the Gateway Labs approach.

"Philadelphia has long led biotech innovation, from early vaccine development to pioneering gene therapy and CAR-T treatments and discovering new approaches to Alzheimer's disease. The local biotech scene builds on that legacy with founders tackling medicine's toughest challenges," said Julie Gilmore, Ph.D., vice president, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management. "Access to top-notch lab infrastructure is essential, but success for early-stage companies also requires experienced thought partners who understand the science and can help navigate the challenging journey from discovery through early clinical development."

Anchored by leading academic medical centers and serving a diverse patient population, Philadelphia has evolved as an upper tier life sciences innovation hub where foundational research rapidly advances toward clinical application. With the addition of Philadelphia, Gateway's U.S. footprint now includes four geographic centers of innovation, including Boston, South San Francisco, and San Diego.

Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than $3 billion, fueling progress on over 50 therapeutic programs.